Cancer ||| S:0 E:6 ||| NNP
/ ||| S:6 E:7 ||| NNP
testis  ||| S:7 E:14 ||| VBD
antigens  ||| S:14 E:23 ||| VBN
for  ||| S:23 E:27 ||| IN
therapeutic  ||| S:27 E:39 ||| JJ
use  ||| S:39 E:43 ||| NN
Since  ||| S:43 E:49 ||| IN
van  ||| S:49 E:53 ||| NNP
der  ||| S:53 E:57 ||| VBD
Bruggen  ||| S:57 E:65 ||| NNP
and  ||| S:65 E:69 ||| CC
colleagues  ||| S:69 E:80 ||| NNS
first  ||| S:80 E:86 ||| RB
identified  ||| S:86 E:97 ||| VBN
specific  ||| S:97 E:106 ||| JJ
human  ||| S:106 E:112 ||| JJ
tumour-associated  ||| S:112 E:130 ||| JJ
antigens  ||| S:130 E:139 ||| NN
of  ||| S:139 E:142 ||| IN
the  ||| S:142 E:146 ||| DT
MAGE  ||| S:146 E:151 ||| NNP
family ||| S:151 E:157 ||| NN
,  ||| S:157 E:159 ||| ,
numerous  ||| S:159 E:168 ||| JJ
potential  ||| S:168 E:178 ||| JJ
immunotherapeutic  ||| S:178 E:196 ||| JJ
targets  ||| S:196 E:204 ||| NNS
have  ||| S:204 E:209 ||| VBP
been  ||| S:209 E:214 ||| VBN
discovered ||| S:214 E:224 ||| VBN
,  ||| S:224 E:226 ||| ,
often  ||| S:226 E:232 ||| RB
belonging  ||| S:232 E:242 ||| VBG
to  ||| S:242 E:245 ||| TO
the  ||| S:245 E:249 ||| DT
so-called  ||| S:249 E:259 ||| JJ
cancer ||| S:259 E:265 ||| NN
/  ||| S:265 E:267 ||| CD
testis  ||| S:267 E:274 ||| JJ
gene  ||| S:274 E:279 ||| NN
family ||| S:279 E:285 ||| NN
.  ||| S:285 E:287 ||| .
Several  ||| S:287 E:295 ||| JJ
members  ||| S:295 E:303 ||| NNS
of  ||| S:303 E:306 ||| IN
this  ||| S:306 E:311 ||| DT
group  ||| S:311 E:317 ||| NN
have  ||| S:317 E:322 ||| VBP
been  ||| S:322 E:327 ||| VBN
described  ||| S:327 E:337 ||| VBN
as  ||| S:337 E:340 ||| IN
immunogenic  ||| S:340 E:352 ||| NN
and  ||| S:352 E:356 ||| CC
have  ||| S:356 E:361 ||| VBP
been  ||| S:361 E:366 ||| VBN
utilised  ||| S:366 E:375 ||| VBN
in  ||| S:375 E:378 ||| IN
clinical  ||| S:378 E:387 ||| JJ
trials ||| S:387 E:393 ||| NNS
.  ||| S:393 E:395 ||| .
In  ||| S:395 E:398 ||| IN
a  ||| S:398 E:400 ||| DT
search  ||| S:400 E:407 ||| NN
for  ||| S:407 E:411 ||| IN
interesting  ||| S:411 E:423 ||| JJ
targets  ||| S:423 E:431 ||| NNS
within  ||| S:431 E:438 ||| IN
this  ||| S:438 E:443 ||| DT
family ||| S:443 E:449 ||| NN
,  ||| S:449 E:451 ||| ,
our  ||| S:451 E:455 ||| PRP$
laboratory  ||| S:455 E:466 ||| NN
has  ||| S:466 E:470 ||| VBZ
focussed  ||| S:470 E:479 ||| VBG
its  ||| S:479 E:483 ||| PRP$
works  ||| S:483 E:489 ||| NNS
for  ||| S:489 E:493 ||| IN
a  ||| S:493 E:495 ||| DT
number  ||| S:495 E:502 ||| NN
of  ||| S:502 E:505 ||| IN
years  ||| S:505 E:511 ||| NNS
on  ||| S:511 E:514 ||| IN
two  ||| S:514 E:518 ||| CD
novel  ||| S:518 E:524 ||| NN
cancer ||| S:524 E:530 ||| NN
/ ||| S:530 E:531 ||| CD
testis  ||| S:531 E:538 ||| CD
antigens  ||| S:538 E:547 ||| NNS
called  ||| S:547 E:554 ||| VBD
T21  ||| S:554 E:558 ||| CD
and  ||| S:558 E:562 ||| CC
HAGE ||| S:562 E:566 ||| NNP
.  ||| S:566 E:568 ||| .
In  ||| S:568 E:571 ||| IN
this  ||| S:571 E:576 ||| DT
article ||| S:576 E:583 ||| NN
,  ||| S:583 E:585 ||| ,
we  ||| S:585 E:588 ||| PRP
will  ||| S:588 E:593 ||| MD
focus  ||| S:593 E:599 ||| VB
our  ||| S:599 E:603 ||| PRP$
discussion  ||| S:603 E:614 ||| NN
on  ||| S:614 E:617 ||| IN
their  ||| S:617 E:623 ||| PRP$
levels  ||| S:623 E:630 ||| NNS
of  ||| S:630 E:633 ||| IN
expression  ||| S:633 E:644 ||| NN
in  ||| S:644 E:647 ||| IN
a  ||| S:647 E:649 ||| DT
wide  ||| S:649 E:654 ||| JJ
variety  ||| S:654 E:662 ||| NN
of  ||| S:662 E:665 ||| IN
both  ||| S:665 E:670 ||| DT
normal  ||| S:670 E:677 ||| JJ
and  ||| S:677 E:681 ||| CC
cancer  ||| S:681 E:688 ||| NN
tissues ||| S:688 E:695 ||| NNS
,  ||| S:695 E:697 ||| ,
their  ||| S:697 E:703 ||| PRP$
possible  ||| S:703 E:712 ||| JJ
role  ||| S:712 E:717 ||| NN
in  ||| S:717 E:720 ||| IN
tumour  ||| S:720 E:727 ||| JJ
cell  ||| S:727 E:732 ||| NN
development  ||| S:732 E:744 ||| NN
and  ||| S:744 E:748 ||| CC
proliferation ||| S:748 E:761 ||| NN
,  ||| S:761 E:763 ||| ,
and  ||| S:763 E:767 ||| CC
their  ||| S:767 E:773 ||| PRP$
immunogenic  ||| S:773 E:785 ||| JJ
potential ||| S:785 E:794 ||| NN
.  ||| S:794 E:796 ||| .
